NEW YORK (GenomeWeb News) – Affymetrix today announced a deal with Massachusetts General Hospital to co-develop cancer biomarker tests using Affy's QuantiGene ViewRNA Assay platform.
As part of the deal, Affy has the commercialization rights to new tests resulting from the collaboration. Other terms were not disclosed.
The QuantiGene ViewRNA Assay is an in situ hybridization assay with single-transcript in single-cell detection capability. The platform is for research-use only.